-
M344: From Chromatin Mechanism to Translation
2026-08-15
M344 is a cell-permeable histone deacetylase inhibitor that connects chromatin remodeling with cancer-cell differentiation, proliferation control, radiation response, and HIV-1 latency research. This article translates its mechanistic and model-specific evidence into a practical framework for experimental design, benchmarking, and translational decision-making.
-
Low-Concentration Chlorhexidine Against E. faecalis
2026-08-14
Sebbane and colleagues show that chlorhexidine inhibits Enterococcus faecalis through coordinated membrane damage, biofilm disruption, and gene-expression changes, even at comparatively low in vitro concentrations. The study provides a mechanistic basis for refining endodontic disinfection research while emphasizing that laboratory activity should not be equated directly with clinical efficacy.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-08-14
This FASEB Journal study developed a localized, nonviral strategy that delivers chemically modified p21 mRNA in lipid nanoparticles directly into the bladder. The approach restored nuclear p21, inhibited tumor growth in an orthotopic mouse model, and limited systemic exposure, providing a useful framework for tumor suppressor replacement therapy.
-
Solanesol: Practical Handling and Assay Guidance
2026-08-13
Solanesol (SKU B8776) is a hydrophobic polyisoprenoid alcohol for controlled biochemical workflows involving membrane-related systems, apoptosis research, DNA damage and repair studies, and enzyme assays. It should be prepared in DMSO rather than water or ethanol, used as a fresh solution when possible, and excluded from diagnostic or medical applications.
-
Ionizing Radiation and Altered Neuronal Differentiation
2026-08-13
Eom et al. showed that ionizing radiation can drive altered neuronal differentiation in C17.2 mouse neural stem-like cells, rather than simply reducing neural stem-cell survival. Their experiments connect neurite outgrowth and neuronal gene expression to coordinated PI3K-STAT3-mGluR1 and PI3K-p53 signaling, providing a mechanistic framework for radiation-associated neural dysfunction.
-
Cell Death in Liver Disease: Mechanisms and Clinical Relevan
2026-08-12
The reference review reframes hepatocellular death as an active driver of inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma rather than merely a consequence of liver injury. Its key practical contribution is a context-dependent framework linking apoptosis, necrosis, necroptosis, damage signals, biomarkers, and therapeutic opportunities across acute and chronic liver disease.
-
3D Nanotube–Micropillar Electrodes in Blood Cell Therapy
2026-08-12
The reference study developed a three-dimensional carbon-nanotube-in-micropillar electrode that improves electroporation across heterogeneous blood-cell populations. By promoting conformal cell–electrode contact and more uniform membrane stimulation, the platform enabled efficient plasmid DNA and RNA delivery in individual cell populations and whole blood, offering a practical nonviral route for cell-therapy research.
-
Bifendate (DDB): Liver Research Workflows
2026-08-11
Build reproducible Bifendate (DDB) experiments for hepatic injury, lipid accumulation, and autophagy studies with solvent-aware preparation and staged controls. The workflow distinguishes compound-specific evidence from transferable assay logic, helping researchers connect cell-based readouts with translational liver models.
-
Vidarabine Monohydrate: Mechanism-Led Assays
2026-08-11
Vidarabine monohydrate is more than a historical antiviral: it is a useful mechanistic probe for separating viral DNA synthesis from cell-level assay artifacts. This guide connects nucleoside pharmacology with orthogonal assay design and evidence-based workflow decisions.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) for LNP Assays
2026-08-10
Discover how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) can resolve mRNA uptake from functional translation in lipid nanoparticle studies. This guide connects dual-fluorescence reporter design with recent solution-based LNP characterization strategies for more informative delivery decisions.
-
FGFR2 Fusion ICC: HDO and Asparagine Depletion
2026-08-09
This study develops a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide that selectively targets the FGFR2-AHCYL1 fusion transcript in intrahepatic cholangiocarcinoma. Its findings also identify EGFR–STAT1–ASNS signaling and asparagine availability as adaptive determinants of response, supporting combination strategies that pair FGFR2-directed treatment with asparagine depletion.
-
FDA-Approved Drug Screening for MERS-CoV Inhibitors
2026-08-08
de Wilde and colleagues screened 348 FDA-approved compounds and identified chloroquine, chlorpromazine, loperamide, and Lopinavir as low-micromolar inhibitors of MERS-CoV replication in cell culture. The study provides a practical repurposing framework while showing why phenotypic antiviral activity must be separated from target-specific mechanism and clinical efficacy.
-
Degarelix Acetate: From Stereochemistry to Assays
2026-08-07
Degarelix acetate is a selective GnRH receptor antagonist with applications spanning receptor pharmacology, pituitary hormone regulation, and prostate cancer research. This article focuses on a critical but underexplored question: how peptide stereochemistry and assay endpoint selection determine the conclusions researchers can safely draw.
-
Redefining Firefly Luciferase mRNA: Deep Dive into 5-moUTP M
2026-08-07
Explore how Firefly Luciferase mRNA engineered with 5-moUTP advances translation efficiency and immune evasion. This article uniquely bridges molecular design and real-world delivery strategies for robust bioluminescent reporter assays.
-
Controlled Protein Dimerization: AP20187 in Translational Re
2026-08-06
Explore how AP20187, a chemical inducer of dimerization, empowers translational researchers to achieve unprecedented precision in controlling protein signaling and gene expression. This article provides a mechanistic overview, experimental guidance, and strategic perspective on the use of AP20187—highlighting its unique role in regulated cell therapy, conditional gene therapy activation, and metabolic pathway research. By integrating evidence from both primary literature and real-world laboratory scenarios, we map the pathway from bench science to transformative clinical potential.